Ir-med, INC

IR-Med, Inc. announced the closing of a private placement offering, issuing common stock and warrants to purchase additional shares, raising $19,054 in gross proceeds.

IR-Med, Inc. completed a private placement offering raising $43,619 and announced the immediate resignation of its CEO, Ran Ziskind, due to strategic disagreements.

IR-Med, Inc. announced financial difficulties, delaying its Q3 2025 10-Q filing and transitioning its CEO and CFO to hourly compensation.

IR-Med, Inc. completed a private placement offering, raising $25,000 through the sale of common stock and warrants, with significant participation from its CEO.

IR-MED, Inc. converted $155,437 of outstanding debt, including accrued interest, into 11,956,692 shares of common stock at $0.013 per share, primarily with company directors.

IR-Med, Inc. completed a private placement offering, raising $64,754 through the sale of common stock and warrants, with significant participation from company directors.

IR-Med, Inc. reported increased losses and significant cash flow challenges, raising substantial doubt about its ability to continue as a going concern.

IR-Med Inc. announces its Q1 2025 financial results, highlighting advancements in its PressureSafe and DiaSafe devices while acknowledging substantial doubt about its ability to continue as a going concern.

IR-Med Inc. reported a reduced net loss for the third quarter of 2024 compared to the same period last year, while progressing with the development and commercialization of its medical devices.

IR-Med, Inc. reported its Q2 2024 financial results, highlighting a decrease in operating expenses and net loss, while also noting substantial doubt about its ability to continue as a going concern.

IR-Med Inc. reported a net loss of $657,000 for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.

IR-Med, Inc. files its 10-K report for 2024, highlighting ongoing development of its PressureSafe and DiaSafe devices amid financial challenges and efforts to secure additional funding.

IR-Med Inc. files an amendment to its annual report to correct disclosures regarding directors, executive officers, and corporate governance, following a period of operational limitations due to financial challenges.

IR-Med, Inc. released its 2023 annual report, detailing financial results and operational updates, including a focus on its PressureSafe device and ongoing financial challenges.

IR-Med, Inc. has filed an amendment to its S-1 registration statement, primarily to update exhibit information related to its proposed sale of common stock.

IR-Med Inc. has filed an amendment to its registration statement for the resale of up to 80 million shares of common stock by Williamsburg Venture Holdings, LLC.

IR-Med Inc. is registering the resale of up to 80 million shares of its common stock by a selling stockholder, Williamsburg Venture Holdings, LLC, to satisfy registration rights granted under an equity purchase agreement.

IR-Med, a medical device company focused on non-invasive diagnostic solutions, has filed an S-1 registration statement for a proposed IPO to list its common stock and warrants on the Nasdaq Capital Market.